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ABSTRACT
Objectives To determine whether gout increases risk of
incident coronary heart disease (CHD), cerebrovascular
(CVD) and peripheral vascular disease (PVD) in a large
cohort of primary care patients with gout, since there have
been no such large studies in primary care.
Methods A retrospective cohort study was performed
using data from the Clinical Practice Research Datalink
(CPRD). Risk of incident CHD, CVD and PVD was
compared in 8386 patients with an incident diagnosis of
gout, and 39 766 age, sex and registered general practice-
matched controls, all aged over 50 years and with no prior
vascular history, in the 10 years following incidence of
gout, or matched index date (baseline). Multivariable Cox
Regression was used to estimate HRs and covariates
included sex and baseline measures of age, Body Mass
Index, smoking, alcohol consumption, Charlson
comorbidity index, history of hypertension, hyperlipidaemia,
chronic kidney disease, statin use and aspirin use.
Results Multivariable analysis showed men were at
increased risk of any vascular event (HRs (95% CIs)) HR
1.06 (1.01 to 1.12), any CHD HR 1.08 (1.01 to 1.15) and
PVD HR 1.18 (1.01 to 1.38), while women were at
increased risk of any vascular event, HR 1.25 (1.15 to
1.35), any CHD HR 1.25 (1.12 to 1.39), and PVD 1.89
(1.50 to 2.38)) but not any CVD.
Conclusions In this cohort of over 50s with gout, female
patients with gout were at greatest risk of incident vascular
events, even after adjustment for vascular risk factors,
despite a higher prevalence of both gout and vascular
disease in men. Further research is required to establish the
reason for this sex difference.
INTRODUCTION
Gout is the most prevalent inﬂammatory arthritis,
affecting an estimated 2.5% of the population in
the UK,1 and 3.9% in North America.2 It is asso-
ciated with elevated levels of serum uric acid (SUA)
and deposition of monosodium urate crystals in
tissues and joints, leading to excruciating painful
attacks of peripheral joint synovitis which, in the
UK, are largely managed in primary care by general
practitioners (GP) who refer on for specialised care
only if necessary.
Hyperuricaemia, the biochemical precursor to
gout, has been linked with an increased incidence
of, and mortality from, both CHD and stroke.3 4
Although gout is traditionally thought of as an
intermittent inﬂammatory condition, recent ultra-
sound studies have identiﬁed persistent subclinical
inﬂammation in the intercritical period between
acute attacks.5 It has been hypothesised that the
combination of persistent inﬂammation and hyper-
uricaemia may potentiate or synergise CHD devel-
opment.6 Deposition of urate crystal material in
vessel walls has been proposed to cause neutrophil
and platelet activation and release of inﬂammatory
mediators that promote cardiovascular damage.7–9
Epidemiological studies examining the relationship
between gout and CHD report conﬂicting ﬁndings,
with a signiﬁcant association reported by some,10–13
but not others,14–16 and investigations of risk of cere-
brovascular disease (CVD) or peripheral vascular
disease (PVD) in patients with gout comparatively
fewer.16–18 Consequently, the risk intrinsic to gout
itself, compared to that from hyperuricaemia or vas-
cular risk factors, such as hypertension and obesity
commonly found in patients with gout, remains
unclear. Additionally, many of these studies have been
conducted in secondary care populations, who may
be characterised by more severe disease, rather than
primary care where the majority of patients with gout
are managed.19
The use of data from routinely collected primary
care records is accepted as a cost-effective way to
undertake epidemiological studies of large patient
populations across a broad population spread.20 The
UK Clinical Practice Research Datalink (CPRD) is the
largest database of electronic primary care health
records (EHR) in the world, and has previously been
used in the study of the association of inﬂammatory
conditions and vascular disease,21 22 as well as in the
epidemiology of gout.1 23
We sought to investigate the association between
gout and incident CHD, CVD and PVD in a large
sample of the UK general practice population.
METHODS
Clinical practice research datalink
The UK CPRD contains data for approximately 9%
of the UK population. Currently, 650 general prac-
tices contribute high-quality data with over 5.5
million active patients,24 thought to be broadly rep-
resentative of the general UK population,24 25 and
high validity of diagnosis in the CPRD has been
reported.26 27
Participant identiﬁcation
Patients consulting in primary care between 1987
and 1999, with an incident diagnosis of gout, were
identiﬁed. Potential control subjects with no history
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of gout were stratiﬁed by general practice, year of birth and sex,
and up to ﬁve were randomly selected from the appropriate
stratum for each patient with gout. Baseline for patients with
gout was considered to be the ﬁrst entry of a diagnostic code
for gout in their EHR, and for patients without gout the date of
diagnosis of gout in their matched gout patient. Pre-baseline
EHRs were searched for codes relating to prescriptions for col-
chicine or urate-lowering therapy, and where these were present,
the patient record was individually examined to determine
whether a prior diagnosis of gout was probable, and subsequent
inclusion or exclusion.
Participants in both cohorts were required to be aged over 50
years at baseline, since vascular events themselves are rare under
the age of 50 years, and are often inﬂuenced by other under-
lying factors which may be difﬁcult to account for. Patients with
a previous history of vascular disease were excluded in order to
minimise the surveillance bias associated with follow-up for a
previous event, and remove the contribution of additional risk
conferred by a previous event.
Outcome measures
Outcomes of interest were time to ﬁrst recording of CHD, CVD
and PVD within the patient’s EHR. Events of interest were
angina, myocardial infarction (MI) and any CHD (including
angina, MI and all less speciﬁc codes describing incident coron-
ary heart disease), stroke/cerebrovascular accident (CVA), transi-
ent ischaemic attack (TIA) and any CVD (including TIA, CVA
and all less speciﬁc codes describing incident cerebrovascular
events) and PVD (considered to be any narrowing of arteries
distal to the arch of the aorta and identiﬁed in the EHR using
codes associated with symptoms at incidence of disease, eg,
intermittent claudication, or asymptomatic identiﬁcation by
screening in high-risk populations, eg, diabetics). The term ‘any
vascular event’ was used to describe overall risk of developing
any of these outcomes of interest. Due to the nature of the
coding, we were not able to separate ischaemic from haemor-
rhagic cerebrovascular events, and for this reason they were con-
sidered together. A list of Read Codes used is available on
request. Participants were followed from baseline until they
experienced an event of interest, or in those who remained
event-free, until the occurrence of death, transfer away from the
practice contributing their records to the CPRD, last collection
of records from the practice by the CPRD, or 10 years from
baseline, whichever was the earliest.
Vascular risk factors
Potential explanatory covariates were chosen by consensus
between GPs and rheumatologists, to represent traditional risk
factors for vascular diseases, well described in the literature, and
used in previous studies of vascular disease.10–12 14 Baseline
data on presence of hypertension, hyperlipidaemia, chronic
kidney disease, Body Mass Index (BMI), ever/never exposure to
alcohol, smoking, statins and aspirin were identiﬁed for all parti-
cipants from their EHR using relevant Read Codes. Smoking
and alcohol data were entered as categorical variables, (ever/
never exposure or missing) in order to minimise the effect that
missing data in the recording of these covariates would have on
the size of the dataset available for analysis. Charlson
Co-morbidity Index28 at baseline was also calculated using a
technique described by Khan et al.29 This index is calculated
based upon the presence or absence of 19 weighted comorbid
conditions, including history of diabetes which was, therefore,
not separately included in the multivariate analysis. Physical
activity and family history of vascular disease were not included
in the multivariable analysis due to high levels of missing data,
and hyperuricaemia could not be included since SUA is not rou-
tinely measured in non-gout patients in the UK.
Statistical analysis
Descriptive statistics were used to describe the baseline demo-
graphics of the sample. Cox proportional hazard modelling was
used to produce both unadjusted and adjusted HRs, estimating
the excess risk of the various forms of vascular disease, asso-
ciated with gout,30 using robust SEs to adjust for any clustering
induced by matching.31 The validity of the proportional hazards
assumption was tested using Schoenfeld residuals and Stata’s
own diagnostic test. Where this assumption was violated, sug-
gesting the risk associated with potential explanatory covariates
may vary over time, the relevant variables were reintroduced
into the model as time-varying covariates.32
Baseline age, BMI, smoking and alcohol exposure and
Charlson comorbidity index, along with sex and gout×sex
interaction were introduced into the ﬁrst model for analysis
(Model 1), in order to minimise surveillance bias and represent
a typical patient with gout presenting to a GP for the ﬁrst time.
Additionally, the second model also included baseline history of
hypertension, hyperlipidaemia, chronic kidney disease and
exposure to prescription statins and aspirin.
The association with vascular events was investigated by sex
subset. The interaction between gout and sex was tested, with
signiﬁcance assessed using the Wald test, since robust SEs were
used. Stratiﬁed effect sizes were calculated in order to clarify sex
differences, using the STATA LINCOM command to calculate
the appropriate linear combinations from the model containing
the interaction. This has the added advantage of using all the
data rather than ﬁtting separate models for sex.33 Data were
analysed using Stata statistical software release 12 (StataCorp:
College Station, TX, 2011).
This study protocol received approval from the Independent
Scientiﬁc Advisory Committee for the Medicines and
Healthcare products Regulatory Agency Database Research (ref-
erence number 10_109)
RESULTS
A total of 8386 patients with gout were age, sex and practice-
matched to 39 766 participants without gout. Mean age at diag-
nosis for patients with gout was 66.3 years (SD 10.8), and 69.4%
were male. Patients with gout had an increased prevalence of all
risk factors of interest at baseline, with the exception of diabetes
mellitus, when compared with non-gout patients (table 1).
The proportional hazards assumption for gout exposure was
met for all types of vascular events. The time-varying covariates
entered for each outcome are available in the online
supplementary table S1.
A statistically signiﬁcant interaction between gout and sex was
found, and for this reason, the results are presented by sex. The
details of the interaction in the gout effect between men and
women are available in the online supplementary table S2.
Totally, 11 266 vascular events occurred during the follow-up
(table 2). Absolute risk of any vascular event per 1000 person
years in men with gout was 43.63 (41.55 to 45.77) compared
to 33.70 (32.86 to 34.55) in men without gout, corresponding
to a crude HR of 1.29 (1.22 to 1.36), and in women with gout
it was 51.89 (48.32 to 55.64) compared to 33.41 (32.15 to
34.71), corresponding to a HR of 1.56 (1.44 to 1.69). The
most marked increase was in risk of PVD in women, where
absolute risk more than doubled, from 3.05 (2.68 to 3.46) to
7.09 (5.81 to 8.55) events per 1000 person-years in women
Clinical and epidemiological research
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with gout, corresponding to an unadjusted HR of 2.35 (1.87 to
2.94). There was a statistically signiﬁcant increased risk of all
vascular outcomes for women with gout, with the exception of
MI, and for men with gout except any CVD and CVA (table 2).
In both sexes, previously identiﬁed risks remained signiﬁcant,
but were attenuated after adjustment for the vascular risk factors
included in model 1 (table 3).
After adjustment for the extended range of covariates
included in model 2, a clear sex difference emerged. Gout was
an independent risk factor for any vascular event, any CHD and
PVD, but not for any of the other vascular outcomes of interest
for men. However, gout remained an independent risk factor
for all types of vascular diseases in women except MI and any
CVD (table 3) and, additionally, the magnitude of risk of all
outcomes was found to be greater in women.
DISCUSSION
This study provides evidence that patients of both sexes with
gout are at increased risk of any vascular events, any CHD and
PVD even after adjustment for traditional vascular risk factors,
but the magnitude of this risk is greater in women. Additionally,
female gout patients are at increased risk of angina, TIA and
CVA, but male patients with gout are not.
While our recent meta-analysis demonstrated an increased
risk of mortality from cardiovascular causes,34 meta-analysis of
risk of incident cardiovascular disease in gout has not been
undertaken to date. Previous studies examining the association
between gout and incident CHD have been conﬂicting; adjusted
results from the Framingham study reported an increased inci-
dence of CHD and angina in men but not women, but both a
prospective study on male health professionals from the USA
and a primary care case-control study using patients of both
sexes with gout from The Netherlands, reported no increased
incidence of CHD.10 14 15 Studies of the association between
gout and MI produce similar conﬂicting reports. Krishnan
et al,11 report an increased incidence of non-fatal and all MI in
a male cohort nested in a controlled trial examining the efﬁcacy
of coronary risk reduction in men at high risk of vascular
disease, DeVera et al,35 report an increased incidence of non-
fatal and all MI in women, but not men in a retrospective
cohort study in Canada, and no association between gout and
MI in either sex reported by Abbott et al, 1988.10
The contradictory nature of current evidence may arise from
signiﬁcant heterogeneity of study design, and ascertainment of
Table 1 Participant demographics at baseline
Gout Non-gout p For significance
Participants, n 8386 39 766
Age at diagnosis, years 66.3 (±10.8) 66.2 (±10.7) 0.99
Male, % 69.4 69.2 0.70
Ever smoker (missing), % 28.3 (23.1) 26.2 (31.2) <0.01
Ever drinker (missing), % 73.5 (13.8) 64.4 (21.2) <0.01
BMI >25 kg/m2 (missing),% 59.7 (18.3) 43.6 (25.0) <0.01
Hypertension, % 36.0 17.3 <0.01
Hyperlipidaemia, % 5.7 3.2 <0.01
Diabetes, % 4.2 4.4 0.33
Chronic kidney disease, % 1.4 0.2 <0.01
Ever statin use, % 34.3 25.6 <0.01
Ever aspirin use, % 42.7 33.4 <0.01
BMI, Body Mass Index
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gout, choice of potential explanatory covariates and study popu-
lations used, all of which (with the exception of one35) are of
smaller size than that used here, and some of which are specia-
lised (e.g. health professionals),12 14 or solely male.11 12 14
The ﬁndings of increased risk of vascular disease in females
are consistent with those of two previous studies.16 35 The
reasons for this increased risk remain unclear, but prolonged
exposure to hyperuricaemia prior to the onset of clinical gout
may play a role, since women have been observed to have an
older mean age at onset of gout, lower mean SUA levels, and
reduced risk of incident gout compared with men with a com-
parable level of hyperuricaemia.36–38 This prolonged exposure
may be lengthened further if clinicians are less vigilant for gout
in women, potentially delaying diagnosis and increasing crystal
and inﬂammatory burden. Incidence of gout is higher in post-
menopausal women,39 suggesting that oestrogen is an important
inﬂuence, both on renal urate handling, and also on the
increased incidence of abdominal obesity and associated hyper-
insulinaemia after menopause which further impairs renal excre-
tion of urate.38 A stronger multiplicative effect between
hyperuricaemia and metabolic vascular risk factors resulting in a
higher propensity of women to hyperuricaemia-induced micro-
vascular damage has also been suggested.40 However, there may
simply be less aggressive management of vascular risk factors or
gout itself in female primary care patients. Although there was a
statistically signiﬁcant difference between the proportions of
male and female patients with gout prescribed allopurinol (43%
vs 39%, p<0.01 for difference) in our sample, a difference of
this magnitude is unlikely to fully explain the sex differences
seen, and further research is required in order to elucidate the
nature of this relationship.
The increased incidence of PVD found in patients of both
sexes with gout is also in line with the only other study to have
examined this relationship.17 This association may result from
common risk factors shared by gout and PVD, such as hyperten-
sion, and chronic kidney disease,41 but further research is
needed to investigate this.
Our ﬁndings have several important implications for clinical
practice. First, current evidence suggests that the clinical man-
agement of gout in primary care is suboptimal,1 42 despite
approximately 1 in 40 people in the UK, and over 8 million
people in the USA currently affected.1 2 Thus, even a small
increase in vascular risk will give rise to a substantial number of
new vascular events. Since there is evidence that cardiovascular
disease in patients with gout often goes unrecognised and
undertreated in primary care, with only a quarter of people con-
sulting with acute gout screened for cardiovascular risk factors
within the subsequent month,43 despite both national and inter-
national guidance recommending this,44–46 the results of this
study suggest a substantial need to change practice. Second,
both gout and vascular disease have historically been considered
diseases of men, and so even in that minority of patients who
are screened for vascular risk factors, those chosen may not be
those most at risk, and since this study highlights the most
serious consequences for women, perhaps more attention
should be paid to prompt and reliable diagnosis of gout, fol-
lowed by optimal management in female patients, including
serious consideration of vascular risk reduction.
Third, screening for PVD in patients with gout is not currently
recommended as part of best practice. The increased risk of inci-
dent PVD was present in both sexes, and was the strongest of
those we identiﬁed. There is evidence that 44% of patients
screened for PVD had PVD without evidence of CHD,47 suggest-
ing that this may not have been detected by routine practice in
primary care, even by those adhering to current guidance on car-
diovascular screening in gout, and suggesting the need for a
change in recommendations to include screening for PVD.
This study has a number of strengths compared with existing
literature. The use of a large number of well-validated primary
care EHR means the study is generalisable to the wider popula-
tion of patients with gout. Additionally, matching patients by
age, sex and GP practice reduces the risk of sociodemographic
confounding. Moreover, the exclusion of patients with a prior
history of vascular events reduces both surveillance bias and the
additional risk conferred by a vascular history, allowing the con-
tribution of gout itself to be more accurately investigated.
The limitations of this study include possible misclassiﬁcation
bias from the use of diagnostic codes to deﬁne either gout,
based upon primary care diagnosis usually made on clinical
grounds, or CHD/CVD outcomes of interest, where termin-
ology may have changed over time or generalised codes may
have been used. Previous studies indicate reasonable validity of
gout diagnosis in primary care.42 43 and other studies under-
taken in the CPRD have selected gout cases using a primary
care diagnosis.1 23 48 Similarly, a recent review of validity of
diagnoses in CPRD reported a positive predictive value of diag-
nosis of MI coded in CPRD of over 80%, with comparable reli-
ability of coding for ischaemic heart disease to other primary
care databases,26 although literature on identiﬁcation of vascular
diseases in EHR databases is sparse.
Table 3 Adjusted risk of vascular disease by sex
Outcome
Model 1 Model 2
HR men
(95% CI)
HR women
(95% CI) p For sex interaction
HR men
(95% CI)
HR women
(95% CI) p For sex interaction
Any vascular 1.22 (1.16 to 1.29) 1.45 (1.34 to 1.57) <0.001 1.06 (1.01 to 1.12) 1.25 (1.15 to 1.35) <0.001
Any CHD 1.26 (1.18 to 1.35) 1.50 (1.35 to 1.67) 0.005 1.08 (1.01 to 1.15) 1.25 (1.12 to 1.39) 0.024
Angina 1.20 (1.08 to 1.34) 1.55 (1.32 to 1.82) 0.010 1.02 (0.92 to 1.13) 1.28 (1.09 to 1.51) 0.003
MI 1.30 (1.15 to 1.46) 1.12 (0.89 to 1.40) 0.254 1.12 (1.00 to 1.27) 0.97 (0.77 to 1.22) 0.263
Any CVD 1.11 (0.97 to 1.26) 1.35 (1.14 to 1.60) 0.068 0.95 (0.83 to 1.09) 1.17 (0.99 to 1.38) 0.058
TIA 1.22 (1.05 to 1.41) 1.50 (1.24 to 1.81) 0.085 1.02 (0.88 to 1.18) 1.26 (1.05 to 1.53) 0.796
CVA 1.08 (0.95 to 1.23) 1.58 (1.35 to 1.84) <0.001 0.93 (0.81 to 1.06) 1.34 (1.15 to 1.57) <0.001
PVD 1.35 (1.16 to 1.58) 2.17 (1.73 to 2.73) <0.001 1.18 (1.01 to 1.38) 1.89 (1.50 to 2.38) 0.04
Model 1 covariates: sex, gout×sex interaction, baseline age, Body Mass Index >25 kg/m2, ever/never smoking, ever/never alcohol consumption, Charlson Comorbidity Score.
Model 2 covariates include Model 1 and baseline history of hypertension, hyperlipidaemia, chronic kidney disease, ever/never statin use, ever/never aspirin use.
CHD, coronary heart disease; CVA, cerebrovascular attack; CVD, cerebrovascular disease; MI, myocardial infarction; PVD, peripheral vascular disease; TIA, transient ischaemic attack.
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While multiple adjustments on risk factors for vascular events
have been performed to take into account differences between
exposed and unexposed groups, we cannot rule out residual
confounding effects. Similarly, while matching by registered
general practice is an accepted method of accounting for socio-
demographic differences, there may be considerable sociodemo-
graphic variation within a practice area that may inﬂuence this
relationship. Furthermore, we were unable to adjust for hyperur-
icaemia (since SUA is not routinely measured in patients without
gout in the UK) and family history of vascular disease and levels
of physical activity in our analysis (due to poor levels of record-
ing), which may have some bearing on this relationship.
However, some degree of the effect of the variables we were
unable to account for is likely to be reﬂected in the other risk
factors included, for example, physical activity and BMI.
In conclusion, this study suggests an association between gout
and subsequent CHD and PVD in both sexes, independent of
traditional vascular risk factors. These risks are greatest in
women, and a particularly strong association between gout and
incident PVD in both sexes was found. Further work is required
to establish the effect of optimum management of both vascular
risk factors and gout itself on the long-term health of gout
patients, clarify the nature of the relationship between gout and
PVD, and the mechanism by which women are at greatest risk.
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